About The Author

Editorial & Columns

Dividend Policy dynamics of Pharmaceutical Companies in India

October 4, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Indian Pharmaceutical Companies: Investment in R&D for “Jai Anusandhan”

September 25, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Forex Rate Risk: Measurement and Mitigation by Pharmaceutical Companies in India

September 14, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Skin in the Game: Decrease in Promoter Holding of Pharmaceutical Companies in India

September 4, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Board Characteristics of Pharmaceutical Companies in India

August 28, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Reporting on Scope 3 Emissions: Learning from Global Pharmaceutical MNCs

August 21, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Different Routes and Same Destination: Indian Pharmaceutical & FMCG Companies in Wellness Segment

August 14, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Risk Management and Pharmaceutical Companies in India

August 6, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Voluntary Licensing in Pharmaceutical Industry: Impact on Market Access & Pricing

August 1, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Divestitures in Pharmaceutical Industry: Indian Experience

July 25, 2024 | Dr. Anil Kumar Angrish | No Comments |

More